ADMINISTRATIVE CORE

UCSD/UCLA DRC的总体使命仅限于促进预防研究 治疗糖尿病及其并发症，最终改善患者的生活。为了过去 十年来，我们的DRC在将两所主要大学的糖尿病/代谢活动联系在一起方面是独一无二的 在UC系统内。我们认为这是一项新的、非常成功的努力；因此，我们有 能够利用加州大学圣地亚哥分校/索尔克分校和加州大学洛杉矶分校/雪松-西奈分校的集体能量和科学兴奋， 这构成了南加州糖尿病/新陈代谢研究的主要比例。刚果民主共和国 促进了这些领域内和跨领域的杰出科学家之间的新的合作和互动 并在促进年轻科学工作者的职业生涯方面发挥了重要作用 独立投资人的地位。我们的研究基地教员成员现在包括109名杰出的 非常成功的科学家，这一点可以从众多的公众人物来判断。 影响力很大的期刊和慷慨的同行评议赠款支持(1.55亿美元)。 过去四年的一些精选亮点包括：(1)儿童糖尿病的组织 加州大学圣迭戈分校研究中心(PDRC)以及拉霍亚过敏和免疫学研究所的增加 (LIAI)在加州大学圣迭戈分校的校区，为刚果民主共和国带来了许多优秀的新教师，所有人都专注于 关于1型糖尿病的研究。(2)更新学院的设立及占用情况 加州大学圣迭戈分校专注于人类干细胞研究和β细胞生成的医学 (3)加州大学洛杉矶分校和加州大学圣迭戈分校的糖尿病/新陈代谢科学家的主要招聘和补充。为 例如，这包括理查德·伯格曼和玛丽莲·阿德，以及他们在雪松-西奈的各自的五个小组， UCSD的Kumar Sharma和LIAI的Matthias von Herrath。(4)我们的P&F奖获得者的杰出成就 随着他们在科学事业中不断向上发展。加州大学洛杉矶分校和加州大学洛杉矶分校承认这一点 已同意每年提供100,000美元的无限制资金，以加强我们的P&F计划。(5)编制 和我们合作的刚果民主共和国教职员工之间的几个项目项目拨款和中心的限制，负责人 作者：克里斯·格拉斯博士、帕姆·梅隆博士、苏珊·泰勒博士、奥尔登·路易斯博士、乔·维茨图姆博士和史蒂夫·杨博士。我们所有的研究 在即将到来的项目中，核心已使用新服务和最先进的技术进行了更新 句号。此外，我们还增加了一个新的目标发现和分析开发核心，以反映 这一领域的许多进展与糖尿病和代谢研究有关。

The overall mission ofthe UCSD/UCLA DRC confinues to center on fostering research in the prevention and treatment of diabetes and its complicafions to ultimately improve the lives of patierits. For the past decade, our DRC has been unique in linking together the diabetes/metabolism activifies of two major universities within the UC system. We believe this has been a novel, and a very successful effort; Thus, we have been able harness the collective energy and scientific excitement at UCSD/Salk and UCLA/Cedars-Sinai, which comprise the major proportion of research in diabetes/metabolism in Southern California. The DRC has fostered new collaborations and interactions between outstanding scienfists within and across these insfitutions and has played an important role in promofing the careers of young scienfists as they move on to the status of independent invesfigators. Our research base faculty membership now includes 109 outstanding scienfists who have been excepfionally successful as can be judged by the numerous publicafions in high impact journals and the generous peer review grant support that they have accrued ($155 million dollars). Some selective highlights over the past four years include: (1) Organizafion of the Pediatric Diabetes Research Center (PDRC) at UCSD along with the addifion of the La Jolla Allergy and Immunology Institute (LIAI) on the UCSD campus, which brings a number of outstanding new faculty into the DRC, all focused exclusively on type 1 diabetes research. (2) Establishment and occupancy of the Institute for Regenerative Medicine on the UCSD campus which has a focus on human stem cell research and beta cell generafion (3) Major recruitments and addifion of diabetes/metabolism-based scientists at both UCLA and UCSD. For example, this includes Richard Bergman and Marilyn Ader, and their respecfive groups, at Cedars-Sinai, Kumar Sharma at UCSD, and Matthias von Herrath at LIAI. (4) Outstanding success of our P&F awardees as they move fonward and upward in their scientific careers. An acknowledgement of this, UCSD and UCLA have agreed to provide $100,000/year in unrestricted funds to augment our P&F program. (5) Establishment and confinuafion of several program project grants and center among our collaborafing DRC faculty, headed by Drs. Chris Glass, Pam Mellon, Susan Taylor, Aldons Lusis, Joe Witztum, and Steve Young. All of our Research cores have been updated with new services and state-of-the-art technologies in the upcoming project period. In addifion, we have added a new Novel Target Discovery and Assay Development Core to reflect the many advances in this field as they relate to diabetes and metabolism research.